Related Experiment Video
Updated: Jan 22, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Novel topical and systemic therapies in atopic dermatitis
1Department of Dermatology, Faculty of Medicine, The University of Tokyo , Tokyo , Japan.
Abstract:
Atopic dermatitis (AD) is the most common inflammatory skin disease driven by both terminal keratinocyte differentiation defects and type 2 immune responses, and this condition causes psychological and social morbidity. Although patients with severe AD require systemic immunotherapy, conventional agents including ciclosporin could not be used for several years due to side effects such as nephrotoxicity, hypertension and long-term risks of malignancy. It is well known that dupilumab, which blocks receptor binding of both IL-4 and IL-13, is remarkably efficacious in the treatment of AD. We have entered a new era when many novel topical and systemic agents that may have great potential in AD treatment are emerging through clinical trials. The purpose of this article is to summarize the efficacy and safety of the current topical and systemic therapies in AD by reviewing recently published papers regarding phase II/III clinical trials. It is revealed that topical phosphodiesterase 4 inhibitors and Janus kinase (JAK) inhibitors are promising treatments for AD. Moreover, systemic therapies such as biologics targeting IL-13 and oral JAK inhibitors show strong efficacy in AD.
Insights
New topical and systemic therapies show promise for atopic dermatitis (AD) treatment. Emerging agents like phosphodiesterase 4 inhibitors and Janus kinase (JAK) inhibitors offer effective options for managing this common inflammatory skin disease.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent inflammatory skin condition with significant psychological and social impact.
- Conventional systemic immunotherapies for severe AD have limitations due to adverse effects like nephrotoxicity and malignancy risks.
- Dupilumab, targeting IL-4 and IL-13, is an established effective treatment for AD.
Purpose of the Study:
- To review the efficacy and safety of current topical and systemic therapies for atopic dermatitis.
- To summarize findings from recently published phase II/III clinical trials on novel AD treatments.
Main Methods:
- Systematic review of published phase II/III clinical trials on atopic dermatitis therapies.
- Analysis of efficacy and safety data for emerging topical and systemic agents.
Main Results:
- Topical phosphodiesterase 4 inhibitors and Janus kinase (JAK) inhibitors demonstrate potential as effective AD treatments.
- Systemic therapies, including biologics targeting IL-13 and oral JAK inhibitors, exhibit strong efficacy in managing AD.
- Novel agents are emerging, heralding a new era in AD therapeutic options.
Conclusions:
- Emerging topical and systemic therapies offer promising advancements in atopic dermatitis management.
- Further research and clinical trials are essential to fully establish the role of these novel agents in AD treatment protocols.
Related Concept Videos
Gene Therapy
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...
Group Therapy
Classification of Systems-I
Homogeneity dictates that if an input x(t) is multiplied by a constant c, the output y(t) is multiplied by the same constant. Mathematically, this is expressed as:

